Lei Jieping, Yang Ting, Liang Chen, Huang Ke, Wu Sinan, Wang Chen
Data and Project Management Unit, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Front Med (Lausanne). 2022 Feb 25;9:817048. doi: 10.3389/fmed.2022.817048. eCollection 2022.
Real-world evidence and comparison among commonly seen chronic obstructive pulmonary disease (COPD) phenotypes, i.e., asthma-COPD overlap (ACO), bronchiectasis-COPD overlap (BCO), and their coexistence (ABCO) have not been fully depicted, especially in Chinese patients.
Data were retrieved from an ongoing nationwide registry in hospitalized patients due to acute exacerbation of COPD in China (ACURE).
Of the eligible 4,813 patients with COPD, 338 (7.02%), 492 (10.22%), and 63 (1.31%) were identified as ACO, BCO, and ABCO phenotypes, respectively. Relatively, the ABCO phenotype had a younger age with a median of 62.99 years [interquartile range (IQR): 55.93-69.48] and the COPD phenotype had an older age with a median of 70.15 years (IQR: 64.37-76.82). The BCO and COPD phenotypes were similar in body mass index with a median of 21.79 kg/m (IQR: 19.47-23.97) and 21.79 kg/m (IQR: 19.49-24.22), respectively. The COPD phenotype had more male gender (79.90%) and smokers (71.12%) with a longer history of smoking (median: 32.45 years, IQR: 0.00-43.91). The ACO and ABCO phenotypes suffered more prior allergic episodes with a proportion of 18.05 and 19.05%, respectively. The ACO phenotype exhibited a higher level of eosinophil and better lung reversibility. Moreover, the four phenotypes showed no significant difference neither in all-cause mortality, intensive care unit admission, length of hospital stay, and COPD Assessment Test score change during the index hospitalization, and nor in the day 30 outcomes, i.e., all-cause mortality, recurrence of exacerbation, all-cause, and exacerbation-related readmission.
The ACO, BCO, ABCO, and COPD phenotypes exhibited distinct clinical features but had no varied short-term prognoses. Further validation in a larger sample is warranted.
真实世界证据以及常见慢性阻塞性肺疾病(COPD)表型,即哮喘-COPD重叠综合征(ACO)、支气管扩张-COPD重叠综合征(BCO)及其共存情况(ABCO)之间的比较尚未得到充分描述,尤其是在中国患者中。
数据取自一项正在进行的中国全国范围内因COPD急性加重住院患者的登记研究(ACURE)。
在符合条件的4813例COPD患者中,分别有338例(7.02%)、492例(10.22%)和63例(1.31%)被确定为ACO、BCO和ABCO表型。相对而言,ABCO表型患者年龄较轻,中位数为62.99岁[四分位间距(IQR):55.93 - 69.48],而COPD表型患者年龄较大,中位数为70.15岁(IQR:64.37 - 76.82)。BCO和COPD表型的体重指数相似,中位数分别为21.79 kg/m²(IQR:19.47 - 23.97)和21.79 kg/m²(IQR:19.49 - 24.22)。COPD表型男性更多(79.90%)且吸烟者更多(71.12%),吸烟史更长(中位数:32.45年,IQR:0.00 - 43.91)。ACO和ABCO表型既往过敏发作更多,比例分别为18.05%和19.05%。ACO表型的嗜酸性粒细胞水平更高且肺可逆性更好。此外,这四种表型在全因死亡率、入住重症监护病房、住院时间以及本次住院期间COPD评估测试评分变化方面均无显著差异,在第30天的结局方面,即全因死亡率、加重复发、全因再入院和加重相关再入院方面也无显著差异。
ACO、BCO、ABCO和COPD表型表现出不同的临床特征,但短期预后无差异。有必要在更大样本中进行进一步验证。